Polar Capital Holdings Plc Has $97.39 Million Stock Holdings in NewAmsterdam Pharma Company N.V. $NAMS

Polar Capital Holdings Plc trimmed its position in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 4.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,776,222 shares of the company’s stock after selling 135,412 shares during the period. Polar Capital Holdings Plc owned about 2.45% of NewAmsterdam Pharma worth $97,390,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of NAMS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in NewAmsterdam Pharma in the 1st quarter worth about $610,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of NewAmsterdam Pharma by 13.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 288,134 shares of the company’s stock valued at $5,898,000 after buying an additional 34,563 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of NewAmsterdam Pharma by 15.9% in the 2nd quarter. Geode Capital Management LLC now owns 99,457 shares of the company’s stock valued at $1,800,000 after buying an additional 13,629 shares in the last quarter. Legal & General Group Plc grew its stake in shares of NewAmsterdam Pharma by 33.5% in the 2nd quarter. Legal & General Group Plc now owns 44,235 shares of the company’s stock valued at $801,000 after buying an additional 11,106 shares in the last quarter. Finally, Invesco Ltd. increased its holdings in NewAmsterdam Pharma by 12.7% in the second quarter. Invesco Ltd. now owns 134,035 shares of the company’s stock worth $2,427,000 after buying an additional 15,101 shares during the last quarter. Institutional investors and hedge funds own 89.89% of the company’s stock.

NewAmsterdam Pharma Trading Down 1.3%

Shares of NewAmsterdam Pharma stock opened at $30.19 on Wednesday. The firm has a fifty day simple moving average of $33.34 and a 200-day simple moving average of $33.50. The stock has a market capitalization of $3.53 billion, a price-to-earnings ratio of -16.87 and a beta of 0.07. NewAmsterdam Pharma Company N.V. has a 1-year low of $17.63 and a 1-year high of $42.21.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its earnings results on Tuesday, March 31st. The company reported ($0.40) EPS for the quarter. The firm had revenue of $3.04 million during the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%. As a group, research analysts predict that NewAmsterdam Pharma Company N.V. will post -1.78 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on NAMS shares. Guggenheim lifted their target price on shares of NewAmsterdam Pharma from $41.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday, February 19th. Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Tuesday, April 21st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of NewAmsterdam Pharma in a research note on Thursday, February 19th. HC Wainwright upgraded shares of NewAmsterdam Pharma to a “strong-buy” rating in a report on Thursday, February 19th. Finally, Wall Street Zen raised shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, NewAmsterdam Pharma presently has a consensus rating of “Moderate Buy” and a consensus target price of $48.60.

Insider Activity at NewAmsterdam Pharma

In other news, CAO Louise Frederika Kooij sold 65,000 shares of NewAmsterdam Pharma stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $35.69, for a total value of $2,319,850.00. Following the transaction, the chief accounting officer directly owned 24,353 shares in the company, valued at approximately $869,158.57. The trade was a 72.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 12.74% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.